-
公开(公告)号：WO2023091168A1
公开(公告)日：2023-05-25
申请号：PCT/US2022/000028
申请日：2022-11-17
IPC分类号： A61K47/54 , A61K31/704 , A61K47/62 , A61K47/69 , A61P35/00
摘要： Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising ICD Prodrugs and methods of making the nanocarriers are disclosed herein. The ICD prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that induce immunogenic cell death (ICD). The ICD Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
-
公开(公告)号：WO2023087482A1
公开(公告)日：2023-05-25
申请号：PCT/CN2021/140245
申请日：2021-12-21
申请人： 苏州大学
IPC分类号： C07K5/083 , C07K1/107 , A61K41/00 , A61K47/64 , A61K47/69 , A61K49/00 , A61K49/10 , A61K49/14 , A61K49/18 , A61P35/00 , B82Y5/00
摘要： 提供了一种亮氨酸氨基肽酶和谷胱甘肽双重刺激响应型探针及其制备方法与应用。所述探针Ce6-Leu在肿瘤微环境的刺激下发生点击缩合反应，继而从纳米颗粒重组装成纳米纤维，具体的，探针Ce6-Leu在肿瘤细胞内过表达的亮氨酸氨基肽酶和谷胱甘肽的刺激下，暴露半胱氨酸结构中原有的氨基和巯基，进而发生点击缩合反应形成两亲性的二聚体，并重组装形成纳米纤维，Ce6结构之间的距离变大，彼此之间的淬灭减弱从而荧光信号和产生ROS的能力增强，进而实现肿瘤的特异性荧光成像和光动力治疗，以及肿瘤的诊疗一体化，具有重要的科研及经济价值。
-
公开(公告)号：WO2023087441A1
公开(公告)日：2023-05-25
申请号：PCT/CN2021/137431
申请日：2021-12-13
申请人： 苏州尔生生物医药有限公司
发明人： 刘密
摘要： 一种预防或治疗癌症的疫苗系统，包括递送粒子及其负载的细胞组分，递送粒子为纳米粒子或微米粒子，细胞组分为来源于一种或一种以上癌细胞和/或肿瘤组织的全细胞组分中的水溶性组分或水溶性组分形成的混合物，或来源于一种或一种以上癌细胞和/或肿瘤组织的全细胞组分中的非水溶性组分或非水溶性组分形成的混合物，疫苗系统可用于癌症的预防和治疗。
-
公开(公告)号：WO2023085440A1
公开(公告)日：2023-05-19
申请号：PCT/JP2022/042459
申请日：2022-11-09
申请人： 公益財団法人東京都医学総合研究所 , 国立大学法人熊本大学
IPC分类号： A61K31/7088 , A61K38/21 , A61K45/00 , A61K47/24 , A61K47/69 , A61P1/16 , A61P31/12 , A61P31/20 , A61P37/04 , A61P43/00 , C12N15/117
摘要： 肝細胞からcccDNAを減少させる又は排除することができる、難治性ウイルス感染症の治療剤等を提供する。本発明に係る難治性ウイルス感染症治療剤は、薬物を細胞内に移送するのに有用な薬物担体に、ポリＩ若しくはポリＩアナログ、及びポリＣ若しくはポリＣアナログを包含する複合体であって、該担体表面に肝細胞への集積能を付与する分子がコンジュゲートされた前記複合体を含有することを特徴とする。
-
公开(公告)号：WO2023083315A1
公开(公告)日：2023-05-19
申请号：PCT/CN2022/131458
申请日：2022-11-11
申请人： 翁炳焕
IPC分类号： A61K39/215 , A61K39/39 , A61K31/7088 , A61K47/54 , A61K47/69 , A61P31/14
摘要： 提供了一种以RBD靶向递送shRNA的nCOVsiRNA药物及其合成方法，该药物是将源自新型冠状病毒受体结合域的RBD作为靶向递送载体，将源自新型冠状病毒及其变异毒株的各毒株共有RNAi序列的siRNA合成shRNA，并使shRNA正反义链分别连接RBD的N端，构成以RBD靶向递送shRNA的具有靶向基因药物和大分子疫苗双重作用的化合物。其中shRNA既是广谱抗病毒药物又是使RBD疫苗增效的免疫佐剂，RBD作为靶向递送载体可避免非靶向治疗的副作用，同时RBD又是蛋白疫苗，其免疫产生的抗-RBD能中和病毒、阻止病毒通过ACE2感染。
-
公开(公告)号：WO2023081765A2
公开(公告)日：2023-05-11
申请号：PCT/US2022/079231
申请日：2022-11-03
发明人： HUBBELL, Jeffrey , WANG, Ruyi , CAO, Shijie , NAGLER, Cathryn R. , WILSON, D. Scott , BASHIR, Mohamed H.
摘要： Provided herein are polymer materials that find use in, for example, delivery of short-chain fatty acids. In particular, polymers are provided that form stable nanoscale structures and release their payload, for example, by cleavage of a covalent bond (e.g., via hydrolysis or enzymatic cleavage). The polymers are useful, for example, for delivery of payloads (e.g., SCFAs) to the intestine for applications in health and treatment of disease, and have broad applicability in diseases linked to changes in the human microbiota including inflammatory, autoimmune, allergic, metabolic, and central nervous system diseases, among others.
-
公开(公告)号：WO2023076944A1
公开(公告)日：2023-05-04
申请号：PCT/US2022/078709
申请日：2022-10-26
摘要： Provided herein are methods of inhibiting tau aggregation in a cell or a subject, comprising administering a LEM domain-containing protein 2 (LEMD2), a charged multivesicular body protein 7 (CHMP7), or an inner nuclear membrane protein Man 1 (LEMD3) or a nucleic acid encoding the LEMD2, the CHMP7, or the LEMD3 to the cell or the subject. Also provided herein are methods of treating or preventing a tauopathy in a subject, comprising administering LEMD2, CHMP7, or LEMD3 or a nucleic acid encoding the LEMD2, the CHMP7, or the LEMD3 to the subject, wherein the LEMD2, the CHMP7, or the LEMD3 inhibits tau aggregation in a cell in the subject. Also provided are nucleic acids encoding LEMD2, CHMP7, or LEMD3 (e.g., in an expression construct and operably linked to a heterologous promoter).
-
公开(公告)号：WO2023060358A1
公开(公告)日：2023-04-20
申请号：PCT/CA2022/051516
申请日：2022-10-14
IPC分类号： C07K19/00 , A61K39/44 , A61K47/64 , A61K47/69 , A61P31/00 , A61P35/00 , A61P37/06 , C07K16/00
摘要： A fusion protein comprises a nanocage monomer or subunit thereof linked to an Fc polypeptide, wherein the Fc polypeptide comprises an IgG4 Fc chain with a mutation at one or more of positions 228, 234, 235, 237, and 238, according to EU numbering, and wherein a plurality of the fusion proteins self-assemble to form a nanocage.
-
9.发明申请
公开(公告)号：WO2023060041A1
公开(公告)日：2023-04-13
申请号：PCT/US2022/077467
申请日：2022-10-03
申请人： DAY, Alexander , MULLIN, Bradford
发明人： DAY, Alexander , MULLIN, Bradford
摘要： Methods and treatments including preparing a synthetic messenger ribonucleic acid (mRNA) encoding at least for a bone morphogenic protein (BMP) and/or a BMP receptor. The synthetic mRNA is lipid-solubilized in a lipid or lipid derivative carrier. Intraoperatively, a bone harvest sample is obtained and incubated with the lipid-solubilized mRNA. The bone harvest sample internalizes at least a portion of the lipid-solubilized mRNA, thereby forming activated BMP and/or BMPR material. The activated BMP and/or BMPR material may be delivered intraoperatively to a bone fusion bed.
-
公开(公告)号：WO2023058022A1
公开(公告)日：2023-04-13
申请号：PCT/IL2022/051057
申请日：2022-10-03
IPC分类号： C07C275/16 , A61K47/69 , A61K47/50 , A61P35/00 , A61P13/08
摘要： This invention, in some embodiments thereof, provides a core- shell nanoparticle including a lipid-PSMA conjugate, encapsulating a liquid oil-based core. The invention further provides aqueous compositions including the core-shell nanoparticles, and methods for using same, such as for the treatment of proliferative diseases associated with PSMA upregulated expression.
-
-
-
-
-
-
-
-
-
搜索结果
985 条记录 (耗时 0.038 秒)
